Next-wave Th1 cytokine cancer therapies aim for more precise targeting
A look at the biology and technology behind next-gen IL-2, IL-12 and IL-18 cancer therapies
A look at the biology and technology behind the next generation of IL-2, IL-12 and IL-18 therapies for cancer.
A growing list of cytokine therapies have been designed to boost cytotoxic immune responses against cancer while sidestepping the limitations of past candidates by controlling where the molecules do and don’t act.
The momentum is particularly strong for cytokines that promote, or are produced by, a subset of CD4+ helper T cells known as “Th1” cells. Supplementing and amplifying the activity of these cells offers a way to “step on